Cagrisema produces greater weight loss than semaglutide in obesity meta-analysis
New analysis shows cagrisema beats semaglutide for weight loss in obesity
This systematic review and meta-analysis of 3,545 individuals with obesity found that cagrisema produced significantly greater weight loss t…
A large meta-analysis found cagrisema produced greater weight loss than semaglutide, while cagrilintide alone matched semaglutide results in…
Oral Semaglutide Failed to Slow Clinical Progression in Early Alzheimer's Disease Across Global Phase 3 Trials
Oral semaglutide did not slow Alzheimer's disease progression in early trials
In large phase 3 trials, oral semaglutide showed no benefit over placebo for patients with early Alzheimer's disease. The drug did not impro…
A large trial found that taking oral semaglutide offered no benefit over placebo for people with early Alzheimer's disease.
CagriSema demonstrates superior weight loss efficacy compared to semaglutide monotherapy or placebo in obesity trials
New drug combo beats standard treatment for obesity and heart risks
A systematic review and meta-analysis of 4,419 patients reveals CagriSema drives greater weight loss than semaglutide alone. However, clinic…
This new drug combination helps people lose more weight and lowers blood pressure, but it causes more stomach upset that needs careful watch…
Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes
New Weight Loss Drug Beats Popular Options in Head-to-Head Comparison
This Bayesian network meta-analysis synthesized evidence from 42 randomized controlled trials, six of which were included in the network, to…
A newer weight loss drug helped people drop nearly 14 percent of their body weight, beating two popular options in a major comparison.
Network Meta-Analysis Finds Tirzepatide and Sleeve Gastrectomy Equally Effective for Weight Loss in Obesity
New Weight Loss Pill Matches Surgery Results Without the Scalpel
A network meta-analysis of 14,293 adults with obesity found that tirzepatide 10 or 15 mg and sleeve gastrectomy achieved similar weight loss…
A diabetes drug now pulls even with stomach surgery for weight loss offering hope to millions who dread going under the knife but it is not …
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
Women Lose More Weight on GLP-1 Drugs Than Men Do
This systematic review and meta-analysis examined weight changes among adults with obesity, diabetes, or cardiovascular disease treated with…
• Women lose 11% weight versus 7% for men on these drugs • Helps adults using Wegovy Ozempic and similar weight loss medications • Works sam…
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
Semaglutide reduces insulin dose in adults with type 1 diabetes and obesity
Semaglutide Cuts Insulin Needs By Half In Type 1 Diabetes
A post hoc analysis of an RCT found that semaglutide 1 mg/week significantly reduced total daily insulin dose by 22.6% over 26 weeks in adul…
Semaglutide reduces insulin needs quickly in type 1 diabetes patients, offering a new hope for better blood sugar control and weight managem…
Semaglutide improves physical quality of life in schizophrenia with prediabetes
Semaglutide improves physical quality of life in adults with schizophrenia and obesity
This secondary analysis of a randomized trial in 154 adults with schizophrenia, prediabetes, and overweight or obesity found that once-weekl…
A secondary analysis of a trial found that once-weekly semaglutide improved physical quality of life in adults with schizophrenia and obesit…
Tirzepatide improves standard and intensive therapeutic target attainment versus semaglutide in adults with type 2 diabetes
New drug helps more patients hit four key health goals at once
This post hoc analysis of a randomised phase 3 study included 1879 adults with type 2 diabetes followed for 40 weeks.
A new diabetes medicine helps more people hit their blood sugar, weight, and blood pressure goals at the same time
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes